Medpace Holdings, Inc. $MEDP Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 560.6% in the third quarter, HoldingsChannel reports. The firm owned 6,130 shares of the company’s stock after buying an additional 5,202 shares during the quarter. SG Americas Securities LLC’s holdings in Medpace were worth $3,152,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clarkston Capital Partners LLC purchased a new position in shares of Medpace during the 2nd quarter worth about $40,569,000. Brighton Jones LLC increased its position in Medpace by 160.4% during the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after purchasing an additional 2,501 shares during the last quarter. Annex Advisory Services LLC increased its position in Medpace by 6.6% during the third quarter. Annex Advisory Services LLC now owns 101,685 shares of the company’s stock worth $52,282,000 after purchasing an additional 6,264 shares during the last quarter. Jump Financial LLC purchased a new position in Medpace during the second quarter worth approximately $15,729,000. Finally, Arkadios Wealth Advisors purchased a new position in Medpace during the second quarter worth approximately $327,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

NASDAQ:MEDP opened at $599.21 on Tuesday. The business’s 50-day moving average is $581.15 and its two-hundred day moving average is $504.33. The firm has a market capitalization of $16.88 billion, a PE ratio of 41.90, a price-to-earnings-growth ratio of 2.00 and a beta of 1.43. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MEDP. BMO Capital Markets started coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. TD Cowen upped their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Barclays raised their price objective on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. Finally, Cowen reissued a “sell” rating on shares of Medpace in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $491.27.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 387,925 shares of company stock valued at $233,386,647 over the last 90 days. 20.30% of the stock is owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.